Rapport Therapeutics is a clinical-stage biotech with strong analyst conviction at a price target implying 49% upside and a 3-for-4 earnings beat streak averaging 9.9% positive surprise, but the company burns cash at -247% of revenue, carries a quality score of 1.9 out of 10, and an extremely elevated put/call ratio of 4.36 signals heavy bearish options activity.
Thesis pillars
- High Analyst Conviction Upside→Stable
- Extreme Put Call Ratio→Stable
- Cash Burn Quality Floor Breach→Stable
- +1 more pillar — see the Why tab for full reasoning
Rapport Therapeutics, Inc. (RAPP) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $38.97: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 18.00; Below-average business quality.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate... Read more
Sell if holding. Engine safety override at $38.97: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 18.00; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Score 5.2/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity. Suitability: speculative.
Recent developments
updated 2026-07-06Recent Developments — Rapport Therapeutics, Inc.
Latest news
- NEWS Leerink Partners Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $52 — benzinga Jun 24, 2026 positive
- NEWS BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $65 — benzinga May 21, 2026 positive
- NEWS Truist Securities Assumes Rapport Therapeutics at Buy, Raises Price Target to $56 — benzinga May 19, 2026 positive
- NEWS BTIG Reiterates Buy on Rapport Therapeutics, Maintains $53 Price Target — benzinga May 8, 2026 positive
- NEWS Rapport Therapeutics Q1 EPS $(0.42) Beats $(0.65) Estimate, Sales $20.000M Beat $8.571M Estimate — benzinga May 7, 2026 positive
Generated 2026-07-06T06:50:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.5% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $38.97: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 18.00; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 63, MACD bullish. Prior stop was $36.24. Score 5.2/10, moderate confidence.
Take-profit target: $49.27 (+26.4% upside). Prior stop was $36.24. Stop-loss: $36.24.
Quality below floor (1.9 < 4.0); Value-trap signals (2/5): Revenue declining (-11.6% YoY), Margin compression (op margin 1.5%).
Rapport Therapeutics, Inc. trades at a P/E of N/A (forward -8.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover RAPP with a consensus score of 4.3/5. Average price target: $57.
What does Rapport Therapeutics, Inc. do?Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and...
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.